Clinical trial
Rasagiline in the Treatment of Persistent Negative Symptoms of Schizophrenia
NCT00492336 · University of Maryland, Baltimore, Other · Completed
Key facts
| NCT number | NCT00492336 |
|---|---|
| Title | Rasagiline in the Treatment of Persistent Negative Symptoms of Schizophrenia |
| Official title | Rasagiline in the Treatment of Persistent Negative Symptoms of Schizophrenia |
| Lead sponsor | University of Maryland, Baltimore, Other |
| Collaborators | Stanley Medical Research Institute |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | rasagiline (Pharmacodynamics), Placebo |
| Enrollment | 84 |
| Start date | Jan 1, 2007 |
| Primary completion | Feb 1, 2012 |
| Completion | Feb 1, 2012 |
| First posted | Jun 27, 2007 |
| Last update posted | Sep 25, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: